CPEB3

Summary

CPEB3 (cytoplasmic polyadenylation element binding protein 3, HGNC:21746) is a protein-coding gene on chromosome 10q23.32, encoding Cytoplasmic polyadenylation element-binding protein 3 (Q8NE35). Sequence-specific RNA-binding protein which acts as a translational repressor in the basal unstimulated state but, following neuronal stimulation, acts as a translational activator.

Enables mRNA 3’-UTR binding activity and translation factor activity, RNA binding. Involved in cellular response to amino acid stimulus and regulation of gene expression. Located in cytoplasm; neuron projection; and nucleus. Part of CCR4-NOT complex.

Source: NCBI Gene 22849 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 103 total
• GTEx eGene: eQTL in 10 tissues, sQTL in 1 (q < 0.05)
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types (inferred from mutation patterns)
• Constraint (gnomAD): pLI 0.60 (intermediate), LOEUF 0.58 (moderately constrained)
• MANE Select transcript: NM_014912
• Notable: 103 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21746
Approved symbol	CPEB3
Name	cytoplasmic polyadenylation element binding protein 3
Location	10q23.32
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0940
Ensembl gene	ENSG00000107864
Ensembl biotype	protein_coding
OMIM	610606
Entrez	22849

Gene structure

Transcript identifiers

Ensembl transcripts: 37 — 33 protein_coding, 4 nonsense_mediated_decay

MANE Select: ENST00000265997

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 5: 1

ENST00000265997, ENST00000412050, ENST00000614585, ENST00000903860, ENST00000903863, ENST00000903866, ENST00000903867, ENST00000903868, ENST00000903869, ENST00000903870, ENST00000903871, ENST00000903872, ENST00000903873, ENST00000903874, ENST00000903875, ENST00000903876, ENST00000903877, ENST00000903878, ENST00000903879, ENST00000903880, ENST00000903881, ENST00000903882, ENST00000903883, ENST00000912186, ENST00000912187, ENST00000912188, ENST00000946416, ENST00000946417, ENST00000946418, ENST00000946419, ENST00000946420, ENST00000990058, ENST00000990059, ENST00001052112, ENST00001052113, ENST00001108328, ENST00001142692

RefSeq mRNA: 2 — MANE Select: NM_014912 NM_001178137, NM_014912

CCDS: CCDS31246, CCDS53553

Canonical transcript exons

ENST00000265997 — 10 exons

Exon	Start	End
ENSE00000713769	92111076	92111194
ENSE00000713776	92144945	92145085
ENSE00000713779	92180963	92181019
ENSE00000810688	92081320	92081501
ENSE00001162650	92046692	92052439
ENSE00001162658	92239346	92240361
ENSE00001252544	92192477	92192636
ENSE00001374446	92290926	92291078
ENSE00002487271	92091830	92091944
ENSE00002490646	92143029	92143118

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 97.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1926 / max 375.3515, expressed in 1387 samples.

Highest expression (Bgee): buccal mucosa cell, endothelial cell, Brodmann (1909) area 23, middle temporal gyrus, postcentral gyrus.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CPEB3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 10 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

11 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Nerve Tibial	eqtl	2.9e-32	-0.43	10:92234054:C:T
Testis	sqtl	5.0e-07	+0.52	10:92121111:A:C
Whole Blood	eqtl	2.9e-04	+0.11	10:92094442:G:A
Spleen	eqtl	6.5e-03	+0.20	10:91540030:T:C
Esophagus Mucosa	eqtl	1.4e-02	-0.08	10:92123389:GCAAGGAC:G
Cells Cultured fibroblasts	eqtl	1.5e-02	+0.21	10:93208459:T:C
Lung	eqtl	1.9e-02	+0.13	10:93214372:G:T
Cells EBV-transformed lymphocytes	eqtl	2.1e-02	+0.22	10:92291231:C:G
Adipose Subcutaneous	eqtl	3.2e-02	-0.11	10:91637944:G:A
Brain Cerebellum	eqtl	3.3e-02	+0.15	10:92397654:C:G
Adrenal Gland	eqtl	3.7e-02	-0.51	10:92706307:C:T

FANTOM5 promoters

showing 10 of 12 alternative TSS:

Promoter ID	TPM avg	Samples expressed
110659	2.5064	725
110658	1.9655	814
110655	1.2703	197
110651	1.1656	382
110656	0.9158	184
110648	0.4596	155
110657	0.4262	246
110647	0.2457	106
110650	0.1216	65
110660	0.0702	10

Top tissues by expression

showing 100 of 284 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.41	gold quality
endothelial cell	CL:0000115	96.89	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.72	gold quality
middle temporal gyrus	UBERON:0002771	92.19	gold quality
postcentral gyrus	UBERON:0002581	90.52	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.08	gold quality
substantia nigra pars compacta	UBERON:0001965	90.06	gold quality
parietal lobe	UBERON:0001872	89.77	gold quality
primary visual cortex	UBERON:0002436	89.57	gold quality
pons	UBERON:0000988	89.42	gold quality
superior frontal gyrus	UBERON:0002661	89.06	gold quality
choroid plexus epithelium	UBERON:0003911	88.28	gold quality
biceps brachii	UBERON:0001507	88.06	gold quality
entorhinal cortex	UBERON:0002728	87.93	gold quality
substantia nigra pars reticulata	UBERON:0001966	87.18	gold quality
occipital lobe	UBERON:0002021	87.16	gold quality
vastus lateralis	UBERON:0001379	85.54	gold quality
superior vestibular nucleus	UBERON:0007227	85.25	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	84.99	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	84.36	gold quality
hindlimb stylopod muscle	UBERON:0004252	84.11	gold quality
quadriceps femoris	UBERON:0001377	83.35	gold quality
cerebellar vermis	UBERON:0004720	83.06	gold quality
sperm	CL:0000019	82.98	gold quality
prefrontal cortex	UBERON:0000451	82.94	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	82.68	gold quality
secondary oocyte	CL:0000655	82.57	gold quality
skeletal muscle organ	UBERON:0014892	82.28	gold quality
muscle organ	UBERON:0001630	82.26	gold quality
muscle of leg	UBERON:0001383	82.00	gold quality
esophagus squamous epithelium	UBERON:0006920	82.00	gold quality
gastrocnemius	UBERON:0001388	81.84	gold quality
frontal cortex	UBERON:0001870	81.53	gold quality
neocortex	UBERON:0001950	81.28	gold quality
medial globus pallidus	UBERON:0002477	81.10	gold quality
cerebral cortex	UBERON:0000956	81.02	gold quality
skeletal muscle tissue	UBERON:0001134	81.00	gold quality
lower esophagus mucosa	UBERON:0035834	80.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.65	gold quality
male germ cell	CL:0000015	80.21	gold quality
temporal lobe	UBERON:0001871	80.13	gold quality
cingulate cortex	UBERON:0003027	79.91	gold quality
anterior cingulate cortex	UBERON:0009835	79.80	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.75	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.62	gold quality
cerebellum	UBERON:0002037	79.54	gold quality
cerebellar cortex	UBERON:0002129	79.49	gold quality
liver	UBERON:0002107	79.44	gold quality
cerebellar hemisphere	UBERON:0002245	79.31	gold quality
oocyte	CL:0000023	78.84	gold quality
telencephalon	UBERON:0001893	78.74	gold quality
right lobe of liver	UBERON:0001114	78.71	gold quality
epithelium of esophagus	UBERON:0001976	78.64	gold quality
cortical plate	UBERON:0005343	78.56	gold quality
muscle tissue	UBERON:0002385	78.27	gold quality
Ammon’s horn	UBERON:0001954	78.24	gold quality
right testis	UBERON:0004534	78.01	gold quality
globus pallidus	UBERON:0001875	78.00	gold quality
brain	UBERON:0000955	77.94	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.91	gold quality
forebrain	UBERON:0001890	77.84	gold quality
left testis	UBERON:0004533	77.66	gold quality
central nervous system	UBERON:0001017	77.63	gold quality
right frontal lobe	UBERON:0002810	77.56	gold quality
calcaneal tendon	UBERON:0003701	77.30	gold quality
palpebral conjunctiva	UBERON:0001812	77.13	gold quality
testis	UBERON:0000473	76.83	gold quality
monocyte	CL:0000576	75.80	gold quality
mononuclear cell	CL:0000842	75.56	gold quality
hypothalamus	UBERON:0001898	75.35	gold quality
amygdala	UBERON:0001876	75.26	gold quality
midbrain	UBERON:0001891	75.22	gold quality
leukocyte	CL:0000738	75.09	gold quality
substantia nigra	UBERON:0002038	74.91	gold quality
ventral tegmental area	UBERON:0002691	74.34	gold quality
nucleus accumbens	UBERON:0001882	74.28	gold quality
esophagus mucosa	UBERON:0002469	73.62	gold quality
caudate nucleus	UBERON:0001873	73.56	gold quality
heart left ventricle	UBERON:0002084	73.32	gold quality
diaphragm	UBERON:0001103	73.18	silver quality
cardiac ventricle	UBERON:0002082	73.03	gold quality
islet of Langerhans	UBERON:0000006	72.95	gold quality
minor salivary gland	UBERON:0001830	72.71	gold quality
esophagus	UBERON:0001043	72.64	gold quality
right atrium auricular region	UBERON:0006631	72.40	gold quality
saliva-secreting gland	UBERON:0001044	72.27	gold quality
medulla oblongata	UBERON:0001896	72.24	gold quality
skin of leg	UBERON:0001511	71.96	gold quality
heart	UBERON:0000948	71.73	gold quality
lower esophagus	UBERON:0013473	71.67	gold quality
lower esophagus muscularis layer	UBERON:0035833	71.62	gold quality
upper leg skin	UBERON:0004262	71.53	gold quality
deltoid	UBERON:0001476	71.51	silver quality
cardiac atrium	UBERON:0002081	71.49	gold quality
squamous epithelium	UBERON:0006914	71.45	gold quality
skin of abdomen	UBERON:0001416	71.43	gold quality
corpus epididymis	UBERON:0004359	71.29	gold quality
mouth mucosa	UBERON:0003729	71.25	gold quality
putamen	UBERON:0001874	71.16	gold quality
adenohypophysis	UBERON:0002196	70.97	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	53.09
E-ANND-3	yes	6.70

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 76 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Postcentral gyrus	tissue	57.6
Cerebral cortex	tissue	43.7
Somatosensory cortex	tissue	43.7
Occipital cortex	tissue	43.4
Pons	tissue	40.4
Thalamus	tissue	39.1
Motor cortex	tissue	38.7
Superior colliculi	tissue	37.8
Retrosplenial and cingulate cortex	tissue	35.6
Olfactory bulb	tissue	35.5
Hippocampal formation	tissue	35.3
Entorhinal cortex	tissue	35.3
Prefrontal cortex	tissue	35.1
Midbrain	tissue	35.0
Retrosplenial cortex	tissue	34.7
Putamen	tissue	34.3
Temporal cortex	tissue	32.8
Substantia nigra	tissue	32.3
Locus coeruleus	tissue	32.3
Insular cortex	tissue	32.2
Hypothalamus	tissue	30.7
Liver	tissue	30.1
Ventral forebrain	tissue	29.7
Cerebellum	tissue	29.1
Medulla oblongata	tissue	28.1
Septum	tissue	27.8
Periaqueductal gray	tissue	27.3
Basal ganglia	tissue	26.8
Choroid plexus	tissue	26.6
Hippocampus	tissue	25.3
Amygdala	tissue	25.2
Frontal cortex	tissue	23.7
Caudate putamen	tissue	22.3
Nucleus accumbens	tissue	21.5
Spinal cord	tissue	21.5
Corpus callosum	tissue	18.7
Skeletal muscle	tissue	18.4
Tongue	tissue	8.9
Testis	tissue	7.2
Salivary gland	tissue	7.1
Retina	tissue	6.6
Thyroid gland	tissue	6.0
Heart muscle	tissue	4.7
Kidney	tissue	4.3
Epididymis	tissue	4.2
Prostate	tissue	4.0
Adrenal gland	tissue	3.7
Pituitary gland	tissue	3.6
Pancreas	tissue	3.3
Breast	tissue	3.0
Parathyroid gland	tissue	3.0
Skin 1	tissue	2.9
Vagina	tissue	2.9
Esophagus	tissue	2.9
Duodenum	tissue	2.9
Small intestine	tissue	2.8
Stomach 1	tissue	2.7
Ovary	tissue	2.6
Rectum	tissue	2.5
Spleen	tissue	2.5

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Nuclei of the trapezoid body (44.7), Postcentral gyrus, middle (43.7), Nucleus raphe magnus (43.5), Paracentral lobule, anterior (41.9), Precentral gyrus (41.7).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting CPEB3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 314 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408

Functional genomics

gnomAD constraint: pLI 0.599, LOEUF 0.585, missense Z 1.29 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000265997 splits into 2 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
10:92,052,215–92,111,101	103 / 251.1	0.41	no
10:92,111,102–92,240,350	643 / 717.5	0.90	no

Literature-anchored findings (GeneRIF, showing 25)

• isolation of a ribozyme conserved mammalian sequence that resides in an intron of the CPEB3 gene (PMID:16990549)
• Secondary structure determination and native gel analyses reveal that the cleaved population of the CPEB3 ribozyme has a single, secondary structure that closely resembles the HDV ribozyme (PMID:20524672)
• Together, these results indicate that Tob mediates the recruitment of Caf1 to the target of CPEB3 and elicits deadenylation and decay of the mRNA. (PMID:21336257)
• cleavage of CPEB3 by NMDA-activated calpain 2 accounts for the activity-related translation of CPEB3-targeted RNAs (PMID:22711986)
• Data suggest that the RNA recognition motif (RRM) domain of CPEB3 (as a soluble peptide fragment) exhibits protein conformation distinct from those of the canonical RRM domain. (PMID:25066254)
• Data show that EGF receptor (EGFR) is involved in the microRNA miR-107 pathogenesis of hepatocellular carcinoma (HCC) through cytoplasmic polyadenylation element binding protein 3 (CPEB3). (PMID:26497556)
• Data show that the expression of cytoplasmic polyadenylation element binding protein 3 (CPEB3) positively correlated with tumor progression and malignancy but negatively correlated with protein phosphorylation in the alternatively spliced region. (PMID:27256982)
• Expression of miR-26a and miR-29a was significantly down regulated in leukoplakia and cancer tissues but up regulated in lichen planus tissues. Expression of target genes such as, ADAMTS7, ATP1B1, COL4A2, CPEB3, CDK6, DNMT3a and PI3KR1 was significantly down regulated in at least two of three disease types with respect to normal tissues. (PMID:27515006)
• SUMO1P3 was upregulated in colorectal cancer tissues and cells and bore prognostic significance. SUMO1P3 epigenetically silenced CPEB3 through EZH2. SUMO1P3 regulated proliferation and apoptosis through CPEB3. (PMID:30799082)
• miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis. (PMID:30834603)
• Here, we performed deep mutational scanning of self-cleaving CPEB3 ribozyme by error-prone PCR and showed that a library of <5 x 104 single-to-triple mutants is sufficient to infer 25 of 26 base pairs including non-nested, nonhelical, and noncanonical base pairs with both sensitivity and precision at 96%. (PMID:31872260)
• NFE2L1 and NFE2L3 Complementarily Maintain Basal Proteasome Activity in Cancer Cells through CPEB3-Mediated Translational Repression. (PMID:32366381)
• LINC00641 hinders the progression of cervical cancer by targeting miR-378a-3p/CPEB3. (PMID:32367630)
• MiR-224 Executes a Tumor Accelerative Role during Hepatocellular Carcinoma Malignancy by Targeting Cytoplasmic Polyadenylation Element-Binding Protein 3. (PMID:32454494)
• CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling. (PMID:32653013)
• CPEB3-mediated MTDH mRNA translational suppression restrains hepatocellular carcinoma progression. (PMID:32968053)
• CPEB3 functions as a tumor suppressor in colorectal cancer via JAK/STAT signaling. (PMID:33146632)
• linc00968 inhibits the tumorigenesis and metastasis of lung adenocarcinoma via serving as a ceRNA against miR-9-5p and increasing CPEB3. (PMID:33159015)
• Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data. (PMID:33506034)
• MiR-20b-5p promotes hepatocellular carcinoma cell proliferation, migration and invasion by down-regulating CPEB3. (PMID:33812045)
• CPEB3 overexpression caused by miR-106b-5p inhibition inhibits esophageal carcinoma in-vitro progression and metastasis. (PMID:35102025)
• CPEB3, an RNA-Binding Protein, Modulates the Behavior of Endometriosis-Derived Stromal Cells via Regulating CXCL12. (PMID:35451884)
• Conformational dynamics in the disordered region of human CPEB3 linked to memory consolidation. (PMID:35658951)
• Phase separation modulates the functional amyloid assembly of human CPEB3. (PMID:37898314)
• MicroRNA-92a-CPEB3 axis protects neurons against inflammatory neurodegeneration. (PMID:38000031)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cpeb3	ENSDARG00000060103
mus_musculus	Cpeb3	ENSMUSG00000039652
rattus_norvegicus	Cpeb3	ENSRNOG00000020689
drosophila_melanogaster	orb2	FBGN0264307
caenorhabditis_elegans		WBGENE00000770
caenorhabditis_elegans		WBGENE00000771

Paralogs (3): CPEB4 (ENSG00000113742), CPEB2 (ENSG00000137449), CPEB1 (ENSG00000214575)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:2443075) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 28 distinct phenotype terms.

Mouse phenotype (MP)	Records
reduced female fertility	2
small ovary	1
impaired ovarian folliculogenesis	1
increased anxiety-related response	1
decreased locomotor activity	1
increased circulating follicle stimulating hormone level	1
abnormal long-term depression	1
decreased litter size	1
decreased corpora lutea number	1
abnormal calcium ion homeostasis	1
abnormal neuron physiology	1
ovary atrophy	1
decreased ovary weight	1
decreased circulating estradiol level	1
abnormal spatial reference memory	1
oocyte degeneration	1
enhanced contextual conditioning behavior	1
abnormal dendritic spine morphology	1
abnormal hippocampus pyramidal cell morphology	1
decreased primordial ovarian follicle number	1
decreased primary ovarian follicle number	1
decreased tertiary ovarian follicle number	1
increased granulosa cell apoptosis	1
decreased granulosa cell proliferation	1
premature ovarian failure	1

+3 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5R733	98.4%	Diamond
Xenopus laevis	Q52KN7	96.8%	Diamond
Carassius auratus	Q9DED5	95.3%	Diamond
Xenopus tropicalis	Q28CH2	86.0%	Diamond
Caenorhabditis briggsae	Q6E3F3	72.0%	Diamond
Caenorhabditis remanei	Q6E3F2	71.3%	Diamond
Aplysia californica	Q967R6	66.8%	Diamond
Caenorhabditis japonica	Q6E3F0	65.4%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
BTAF1	protein-coding	9044
IDE	protein-coding	3416
MARCHF5	protein-coding	54708
FGFBP3-AS1	ncRNA	140577504
FGFBP3	protein-coding	143282
TNKS2-DT	ncRNA	100507633
TNKS2	protein-coding	80351

Protein

Protein identifiers

Cytoplasmic polyadenylation element-binding protein 3 — Q8NE35 (reviewed: Q8NE35)

All UniProt accessions (2): Q8NE35, Q5QP71

UniProt curated annotations — full annotation on UniProt →

Function. Sequence-specific RNA-binding protein which acts as a translational repressor in the basal unstimulated state but, following neuronal stimulation, acts as a translational activator. In contrast to CPEB1, does not bind to the cytoplasmic polyadenylation element (CPE), a uridine-rich sequence element within the mRNA 3’-UTR, but binds to a U-rich loop within a stem-loop structure. Required for the consolidation and maintenance of hippocampal-based long term memory. In the basal state, binds to the mRNA 3’-UTR of the glutamate receptors GRIA2/GLUR2 mRNA and negatively regulates their translation. Also represses the translation of DLG4, GRIN1, GRIN2A and GRIN2B. When activated, acts as a translational activator of GRIA1 and GRIA2. In the basal state, suppresses SUMO2 translation but activates it following neuronal stimulation. Binds to the 3’-UTR of TRPV1 mRNA and represses TRPV1 translation which is required to maintain normal thermoception. Binds actin mRNA, leading to actin translational repression in the basal state and to translational activation following neuronal stimulation. Negatively regulates target mRNA levels by binding to TOB1 which recruits CNOT7/CAF1 to a ternary complex and this leads to target mRNA deadenylation and decay. In addition to its role in translation, binds to and inhibits the transcriptional activation activity of STAT5B without affecting its dimerization or DNA-binding activity. This, in turn, represses transcription of the STAT5B target gene EGFR which has been shown to play a role in enhancing learning and memory performance. In contrast to CPEB1, CPEB2 and CPEB4, not required for cell cycle progression.

Subunit / interactions. Following synaptic activity, forms amyloid-like oligomers. Aggregation requires an intact actin cytoskeleton. Interacts with STAT5B; this inhibits STAT5B-mediated transcriptional activation. Interacts with E3 ubiquitin-protein ligase NEURL1; this leads to monoubiquitination and activation of CPEB3. Interacts with CAPN2; this leads to cleavage of CPEB3. Interacts (via C-terminal RNA-binding region) with TOB1; TOB1 also binds CNOT7/CAF1 and recruits it to CPEB3 to form a ternary complex. Interacts with SUMO-conjugating enzyme UBC9. Interacts with IPO5; the interaction is enhanced in a RAN-regulated manner following neuronal stimulation and mediates CPEB3 nuclear import. Interacts with exportin XPO1/CRM1.

Subcellular location. Cytoplasm. Nucleus. Synapse. Cell projection. Dendrite. Postsynaptic density.

Post-translational modifications. Activated by NEURL1-mediated monoubiquitination, resulting in the growth of new dendritic spines and increased levels of GRIA1 and GRIA2. NEURL1-mediated monoubiquitination facilitates synaptic plasticity and hippocampal-dependent memory storage. Under basal unstimulated conditions when CPEB3 is mainly unaggregated, sumoylated and acts as a translational repressor. Following neuronal stimulation, becomes desumoylated and aggregated which is required for the translation of mRNA targets and for dendritic filopodia formation. Following neuronal stimulation, cleaved by CAPN2 which abolishes its translational repressor activity, leading to translation of CPEB3 target mRNAs. Phosphorylation is enhanced by neuronal stimulation.

Domain organisation. The N-terminal Gln-rich region is required for the formation of amyloid-like oligomers and for the stability of long-term potentiation and spatial memory.

Miscellaneous. The CPEB3 gene contains an intron-encoded self-cleaving ribozyme which is structurally and biochemically related to human hepatitis delta virus ribozymes and which may play a role in the regulation of CPEB3 translation. A polymorphism in the ribozyme sequence which influences cleavage activity of the ribozyme may play a role in episodic memory with carriers of a rare C allele-containing ribozyme showing significantly poorer memory recall performance than T allele carriers.

Similarity. Belongs to the RRM CPEB family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8NE35-1	1	yes
Q8NE35-2	2

RefSeq proteins (2): NP_001171608, NP_055727* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR032296	CEBP_ZZ	Domain
IPR034819	CPEB	Family
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR038446	CEBP_ZZ_sf	Homologous_superfamily

Pfam: PF16366, PF16367

UniProt features (49 total): mutagenesis site 13, strand 10, compositionally biased region 7, modified residue 4, site 3, domain 2, splice variant 2, region of interest 2, helix 2, chain 1, sequence variant 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

6 structures by resolution:

PDB	Title	Method	Resolution (Å)
7N2E	MicroED structure of human CPEB3 segment (154-161) straight polymorph	ELECTRON CRYSTALLOGRAPHY	1
7N2F	MicroED structure of human CPEB3 segment (154-161) straight polymorph phased by …	ELECTRON CRYSTALLOGRAPHY	1.2
7N2G	MicroED structure of human CPEB3 segment(154-161) kinked polymorph phased by …	ELECTRON CRYSTALLOGRAPHY	1.2
8SPA	Structural insights into cellular control of the human CPEB3 prion, functionally …	ELECTRON MICROSCOPY	3
2DNL	Solution structure of RNA binding domain in Cytoplasmic polyadenylation element binding …	SOLUTION NMR
2RUG	Refined solution structure of the first RNA recognition motif domain in CPEB3	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NE35-F1	58.59	0.29

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol; midbody; nucleoplasm; plasma membrane

Antibody reliability (HPA): IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3)

Position	Role
441–442	cleavage; by capn2
444	required for rna-binding activity
488	required for rna-binding activity

Post-translational modifications (4)

Type	Positions
Phosphoserine	192, 195, 290
Asymmetric dimethylarginine	308

Mutagenesis-validated functional residues (13)

Position	Phenotype
349	abolishes nuclear export; when associated with a-353.
353	abolishes nuclear export; when associated with a-349.
441	does not impair rna binding.
444	abolishes rna binding.
444	does not impair rna binding.
446	does not impair rna binding.
463	does not impair rna binding.
470	does not impair rna binding.
474	does not impair rna binding.
479	does not impair rna binding.
488	reduced rna binding.
488	does not impair rna binding.
528	does not impair rna binding.

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 438 (showing top): GOBP_CYTOPLASMIC_TRANSLATION, GOBP_DENDRITE_DEVELOPMENT, GOBP_MEMORY, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_COGNITION, GOBP_BEHAVIOR, MORF_MSH3, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOBP_RESPONSE_TO_ACID_CHEMICAL, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_SYNAPSE_ASSEMBLY, SP3_Q3, ATACCTC_MIR202, MORF_BRCA1, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP

GO Biological Process (16): negative regulation of transcription by RNA polymerase II (GO:0000122), long-term memory (GO:0007616), negative regulation of translation (GO:0017148), positive regulation of translation (GO:0045727), regulation of synaptic plasticity (GO:0048167), positive regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060213), regulation of dendritic spine development (GO:0060998), positive regulation of dendritic spine development (GO:0060999), 3’-UTR-mediated mRNA destabilization (GO:0061158), cellular response to amino acid stimulus (GO:0071230), regulation of postsynapse assembly (GO:0150052), positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:1900153), negative regulation of cytoplasmic translational elongation (GO:1900248), negative regulation of cytoplasmic translation (GO:2000766), translation (GO:0006412), regulation of translation (GO:0006417)

GO Molecular Function (10): mRNA regulatory element binding translation repressor activity (GO:0000900), RNA binding (GO:0003723), mRNA 3’-UTR binding (GO:0003730), translation factor activity, RNA binding (GO:0008135), RNA stem-loop binding (GO:0035613), mRNA 3’-UTR AU-rich region binding (GO:0035925), ribosome binding (GO:0043022), nucleic acid binding (GO:0003676), protein binding (GO:0005515), translation regulator activity (GO:0045182)

GO Cellular Component (9): nucleus (GO:0005634), cytoplasm (GO:0005737), postsynaptic density (GO:0014069), CCR4-NOT complex (GO:0030014), dendrite (GO:0030425), neuron projection (GO:0043005), synapse (GO:0045202), apical dendrite (GO:0097440), postsynapse (GO:0098794)

GO top-level categories

showing 60 of 64 GO namespaces:

Category	Terms
translation	4
regulation of translation	3
positive regulation of mRNA catabolic process	2
dendritic spine development	2
mRNA binding	2
RNA binding	2
binding	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
memory	1
negative regulation of gene expression	1
negative regulation of protein metabolic process	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
nuclear-transcribed mRNA poly(A) tail shortening	1
regulation of nuclear-transcribed mRNA poly(A) tail shortening	1
regulation of developmental process	1
positive regulation of developmental process	1
regulation of dendritic spine development	1
mRNA destabilization	1
response to amino acid	1
cellular response to acid chemical	1
regulation of synapse assembly	1
postsynapse assembly	1
regulation of postsynapse organization	1
nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	1
regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	1
cytoplasmic translational elongation	1
negative regulation of translational elongation	1
regulation of cytoplasmic translational elongation	1
negative regulation of cytoplasmic translation	1
cytoplasmic translation	1
negative regulation of translation	1
regulation of cytoplasmic translation	1
peptidyltransferase activity	1
translational initiation	1
translational elongation	1
translational termination	1
macromolecule biosynthetic process	1
protein metabolic process	1
protein biosynthetic process	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
translation repressor activity	1
nucleic acid binding	1
translation factor activity	1
mRNA 3’-UTR binding	1
ribonucleoprotein complex binding	1
molecular_function	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
asymmetric synapse	1
postsynaptic specialization	1
intracellular protein-containing complex	1
neuron projection	1
dendritic tree	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 13 of 35 annotations. The rest are phylogenetic / computational / electronic (IEA).

13 experimentally-supported GO terms:

GO term	NS	Evidence
3’-UTR-mediated mRNA destabilization	BP	direct assay
cellular response to amino acid stimulus	BP	direct assay
negative regulation of transcription by RNA polymerase II	BP	direct assay
negative regulation of translation	BP	direct assay
positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay	BP	direct assay
positive regulation of nuclear-transcribed mRNA poly(A) tail shortening	BP	direct assay
CCR4-NOT complex	CC	direct assay
cytoplasm	CC	direct assay
neuron projection	CC	direct assay
nucleus	CC	direct assay
RNA binding	MF	direct assay
mRNA 3’-UTR binding	MF	direct assay
translation factor activity, RNA binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 784 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CPEB3	OR4K15	Q8NH41	921
CPEB3	FXR1	P51114	623
CPEB3	IGF1R	P08069	528
CPEB3	TENT2	Q6PIY7	525
CPEB3	FXR2	P51116	497
CPEB3	FMR1	Q06787	492
CPEB3	PNKP	Q96T60	491
CPEB3	PAPOLB	Q9NRJ5	424
CPEB3	PAPOLG	Q9BWT3	421
CPEB3	PAPOLA	P51003	420
CPEB3	SYMPK	Q92797	393
CPEB3	GRIA1	P42261	388
CPEB3	EIF4E	P06730	375
CPEB3	RNF130	Q86XS8	365
CPEB3	LEO1	Q8WVC0	364

IntAct

Human interaction partners of CPEB3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

3 partners by confidence:

Partner	Interaction type	MIscore	Records
TOB1	association	0.650	7
TOB2	physical association	0.400	1
TNIK	physical association	0.000	1

BioGRID (10 interactions; top human partners by supporting records): CPEB4 (Affinity Capture-MS), EGLN3 (Affinity Capture-MS), KIAA1429 (Affinity Capture-RNA), NUDT21 (Affinity Capture-RNA), NXF1 (Affinity Capture-RNA)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
NEURL1	“up-regulates activity”	CPEB3	ubiquitination

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — BCC.

intOGen’s role is a computational inference from cohort mutation patterns and may diverge from the gene’s curated/literature role; read it alongside the evidence above.

Genetic variants

Variant evidence for CPEB3: 103 ClinVar records (0 pathogenic / likely pathogenic); 2 GWAS associations.

ClinVar

103 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	91
Likely benign	1
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 2,235):

Position(s)	Effect	Δscore	Sites
10:92081318–92081319	donor_loss	1.0000	4
10:92081502–92081503	acceptor_loss	1.0000	4
10:92081506	acceptor_gain	1.0000
10:92091828–92091829	donor_loss	1.0000	5
10:92111074–92111075	donor_loss	1.0000	5
10:92111195–92111196	acceptor_gain	1.0000	2
10:92111195–92111196	acceptor_loss	1.0000	4
10:92111207	acceptor_gain	1.0000
10:92143027–92143028	donor_loss	1.0000	5
10:92143119–92143120	acceptor_loss	1.0000	5

AlphaMissense

2,365 missense substitutions predicted likely pathogenic (of 4,603 scored), across 494 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M569	9	0.994	1.000
F444	8	1.000	1.000
D451	8	1.000	1.000
F552	8	1.000	1.000
D582	8	1.000	1.000
F598	8	1.000	1.000
H671	8	1.000	1.000
H679	8	1.000	1.000
F461	8	0.999	1.000
D584	8	0.999	1.000
D637	8	0.999	1.000
D470	8	0.998	1.000
F481	8	0.998	1.000
F488	8	0.998	1.000
S517	8	0.998	1.000
D632	8	0.998	1.000
F652	8	0.998	1.000
D453	8	0.997	0.999
H473	8	0.997	1.000
F491	8	0.996	1.000

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

8 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (validation)	favorable	2.64e-06
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	3.41e-05
Head and Neck Squamous Cell Carcinoma (TCGA)	favorable	0.000194
Liver Hepatocellular Carcinoma (TCGA)	favorable	0.000316
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000344
Bladder Urothelial Carcinoma (TCGA)	favorable	0.000676
Colon Adenocarcinoma (validation)	unfavorable	0.000827
Glioblastoma Multiforme (validation)	favorable	0.000986

Disease associations

OMIM: gene MIM:610606 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

GWAS associations

2 associations:

Study	Trait	p-value
GCST90002394_224	Monocyte percentage of white cells	9e-10
GCST007576_305	Chronotype	2e-9

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0008328	chronotype measurement
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	4
Benzo(a)pyrene	decreases expression, decreases methylation	3
Valproic Acid	increases expression	3
Arsenic	increases abundance, increases expression, affects methylation	2
Cadmium	decreases expression, increases abundance, decreases reaction	2
Silicon Dioxide	decreases expression, increases methylation	2
Tetrachlorodibenzodioxin	decreases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, decreases expression	2
bisphenol A	affects cotreatment, increases methylation	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
nickel sulfate	decreases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
clothianidin	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Atrazine	increases expression	1
Calcitriol	increases expression, affects cotreatment	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects binding, increases expression	1
Doxorubicin	decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Folic Acid	decreases expression	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 185 trials:

NCT	Phase	Status	Title
NCT00152750	Phase 4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	Phase 4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	Phase 4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	Phase 4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	Phase 4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	Phase 4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	Phase 4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	Phase 3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	Phase 3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	Phase 3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	Phase 3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	Phase 3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	Phase 3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	Phase 3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	Phase 3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	Phase 3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	Phase 3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	Phase 3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	Phase 2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	Phase 2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	Phase 2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	Phase 2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	Phase 2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	Phase 2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	Phase 2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	Phase 2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	Phase 2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	Phase 2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	Phase 2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	Phase 2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	Phase 2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	Phase 2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	Phase 2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	Phase 2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	Phase 2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	Phase 2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	Phase 2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	Phase 2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	Phase 2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	Phase 2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03530293	Phase 2	TERMINATED	Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
NCT03625453	Phase 2	COMPLETED	Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder
NCT03651726	Phase 2	UNKNOWN	A Study to Examine the Efficacy of a Therapeutic THX-110 for Tourette Syndrome
NCT03732534	Phase 2	TERMINATED	Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
NCT03944447	Phase 2	UNKNOWN	Outcomes Mandate National Integration With Cannabis as Medicine
NCT04007991	Phase 2	COMPLETED	Ecopipam Tablets to Study Tourette’s Syndrome in Children and Adolescents
NCT04354103	Phase 2	TERMINATED	Atomoxetine in Patients With Tourette’s Syndrome
NCT04978428	Phase 2	COMPLETED	Epidiolex in Obsessive Compulsive Disorder and Related Disorders
NCT05126888	Phase 2	NOT_YET_RECRUITING	SCI-110 in the Treatment of Tourette Syndrome
NCT05434546	Phase 2	COMPLETED	A Study to Explore the Effect of Sepranolone in Tourette Syndrome
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06194305	Phase 2	RECRUITING	Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
NCT06315751	Phase 2	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06678737	Phase 2	RECRUITING	CBIT+TMS R33 Phase
NCT00139308	Phase 1	COMPLETED	High Frequency Stimulation of the GPi or Thalamus in Tourette’s Syndrome
NCT00634556	Phase 1	COMPLETED	Dopaminergic Effects on Cortical Function in Tourette’s (Levodopa Protocol)
NCT00952601	Phase 1	TERMINATED	Pilot Study of the Modified Atkins Diet for Tourette Syndrome
NCT01440023	Phase 1	COMPLETED	Developing Cognitive Training for Tourette Syndrome
NCT01719523	Phase 1	COMPLETED	Open-Trial of EPI-743 for Adults With Tourette Syndrome
NCT02134080	Phase 1	TERMINATED	FAAH Inhibitor Trial for Adults With Tourette Syndrome